Maduck Sean's Form 4 filing
Corcept Therapeutics Inc (CORT) · filed Aug 5, 2025
- Accession no.
- 0000950170-25-103324
- Filed
- Aug 5, 2025
- Trade date
- Jun 12-Aug 1, 2025
- Filing delay
- 54 daysLate
- Rule 10b5-1 plan
- Checked
This filing lists 8 non-derivative transactions and 1 derivative transaction. Open-market sales total $2.37M. It was filed 54 days after the trade, past the 2-business-day deadline.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Maduck SeanCIK 0001698310 | Officer (See Remarks) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jun 12, 2025 | Common Stock | GGiftDisposed | −10,024 | $0.00 | $0 | 7,681 | Direct | |
| Jun 12, 2025 | Common Stock | JOtherAcquired | +10,024 | $0.00 | $0 | 99,717 | Indirect | |
| Jul 3, 2025 | Common Stock | GGiftDisposed | −40,000 | $0.00 | $0 | 59,717 | Indirect | |
| Jul 3, 2025 | Common Stock | JOtherAcquired | +40,000 | $0.00 | $0 | 40,000 | Indirect | |
| Aug 1, 2025 | Common Stock | MOption exerciseAcquired | +35,007 | $5.05 | +$176,785.35 | 42,688 | Direct | |
| Aug 1, 2025 | Common Stock | SSaleDisposed | −27,865 | $67.53F7 | −$1,881,723.45 | 14,823 | Direct | |
| Aug 1, 2025 | Common Stock | SSaleDisposed | −5,428 | $68.52F8 | −$371,926.56 | 9,395 | Direct | |
| Aug 1, 2025 | Common Stock | SSaleDisposed | −1,714 | $69.70F9 | −$119,465.8 | 7,681 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 1, 2025 | Common Stock | MOption exerciseDisposed | −35,007 | $0.00 | $0 | 21,986 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F7
Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $67.17 to $68.10 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
Referenced by the price of 1 transaction in Table I.
- F8
Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $68.17 to $69.13 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
Referenced by the price of 1 transaction in Table I.
- F9
Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $69.48 to $69.74 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
Referenced by the price of 1 transaction in Table I.
Remarks
President, Corcept Endocrinology The power of attorney under which this form was signed is on file with the Commission.